AGL

agilon health inc

Add to Watchlist

Advanced Chart

0.863

-0.01(-1.145%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.8844

Open

0.8375

VWAP

0.85

Vol

12.89M

Mkt Cap

357.77M

Low

0.8244

Amount

10.96M

EV/EBITDA(TTM)

Total Shares

411.26M

69.98M

EV/OCF(TTM)

P/S(TTM)

0.06

agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.77B

+15.7%

0.056

-768.42%

1.50B

-1.71%

-0.081

-67.75%

1.50B

+3.54%

-0.040

-85.56%

Estimates Revision

The market is revising Upward the revenue expectations for agilon health, inc. (AGL) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by -70.93%.

Revenue Estimates for FY2025

Revise Upward

+0.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.51%

In Past 3 Month

Stock Price

Go Down

-70.93%

In Past 3 Month

13 Analyst Rating

157.15% Upside

Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 2.22 USD with a low forecast of 1.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

7 Hold

2 Sell

Hold

157.15% Upside

Current: 0.863

Low

1.00

Averages

2.22

High

5.00

157.15% Upside

Current: 0.863

Low

1.00

Averages

2.22

High

5.00

TD Cowen

Hold

downgrade

$4 -> $1

2025-08-06

Reason

TD Cowen

Price Target

$4 -> $1

2025-08-06

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Agilon Health to $1 from $4 and keeps a Hold rating on the shares. The firm noted they pre-announced a material revenue/medical margin/adj EBITDA miss primarily due to RAF revisions and unfavorable PYD. The company withdrew its 2025 guidance and announced its CEO stepped down and is searching for a replacement.

Benchmark

Buy

downgrade

2025-08-06

Reason

Benchmark

Price Target

2025-08-06

downgrade

Buy

Reason

Benchmark lowered the firm's price target on Agilon Health to $1.50 from $4 and keeps a Buy rating on the shares. The stock was "cut roughly in half yesterday" after Agilon reported a wide Q2 miss, suspended FY25 guidance, and announced that CEO Steven Sell had stepped down, the analyst noted. Given the "positive trends still in place for 2026," and with the stock now selling just slightly above cash per share, the firm reduced its target but maintains a Buy rating.

Citi

Buy -> Neutral

downgrade

$3 -> $1

2025-08-05

Reason

Citi

Price Target

$3 -> $1

2025-08-05

downgrade

Buy -> Neutral

Reason

Citi downgraded Agilon Health to Neutral from Buy with a price target of $1, down from $3 after its Q2 results and pulled guidance. The company's Q2 earnings miss was largely driven by limited risk scoring visibility, concentrated in two payors, the analyst tells investors in a research note. Citi adds that the firm had caught-up with the management this afternoon, noting that while the conversation offered confidence that the issues AGL experienced are not structural, AGL's visibility remains limited, which will keep the shares range-bound in the near term.

Wells Fargo

Stephen Baxter

Overweight

downgrade

$6 -> $5

2025-05-13

Reason

Wells Fargo

Stephen Baxter

Price Target

$6 -> $5

2025-05-13

downgrade

Overweight

Reason

Wells Fargo analyst Stephen Baxter lowered the firm's price target on Agilon Health to $5 from $6 and keeps an Overweight rating on the shares. The firm cites a "frustrating quarter" given the PYD issues. The thesis remains largely unchanged, with Wells continuing to see positive leverage to improving MA rates and downstream margin recovery story. The firm is lowering forward revenue/profit somewhat to account for Agilon's expected trajectory.

Barclays

Underweight

maintain

$2 -> $3

2025-05-08

Reason

Barclays

Price Target

$2 -> $3

2025-05-08

maintain

Underweight

Reason

Barclays raised the firm's price target on Agilon Health to $3 from $2 and keeps an Underweight rating on the shares. Despite a Q1 headline beat, the company's "soft" Q2 guidance and lingering uncertainty on Part D / Group Medicare Advantage risk in the market are "reasons for continued caution," the analyst tells investors in a research note.

Citi

Neutral -> Buy

upgrade

2025-04-25

Reason

Citi

Price Target

2025-04-25

upgrade

Neutral -> Buy

Reason

Citi upgraded Agilon Health (AGL) to Buy from Neutral with a price target of $5, up from $3.25. The company has done an "admirable job" reducing risk in 2025 and should see accelerated margin improvement in 2026 and 2027 given the better than anticipated 2026 final rate notice, the analyst tells investors in a research note. The firm thinks the stock's 30% selloff post UnitedHealth (UNH) earnings is overdone as its recent conversation with Aledade co-Founder and CEO Farzad Mostashari gives it confidence that the magnitude of the company's issues are largely idiosyncratic to its Optum strategy. Agilon has a better field of vision to properly manage risk across plans when there is significant switching among the national insurers, contends Citi.

See All Ratings

Valuation Metrics

The current forward P/E ratio for agilon health inc (AGL.N) is -2.72, compared to its 5-year average forward P/E of -29.24. For a more detailed relative valuation and DCF analysis to assess agilon health inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-29.24

Current PE

-2.72

Overvalued PE

269.95

Undervalued PE

-328.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

113.83

Current EV/EBITDA

-0.71

Overvalued EV/EBITDA

627.50

Undervalued EV/EBITDA

-399.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.08

Current PS

0.06

Overvalued PS

4.09

Undervalued PS

0.07

Financials

Annual

Quarterly

FY2025Q2

YoY :

-5.92%

1.39B

Total Revenue

FY2025Q2

YoY :

+167.69%

-116.03M

Operating Profit

FY2025Q2

YoY :

+240.39%

-104.37M

Net Income after Tax

FY2025Q2

YoY :

+257.14%

-0.25

EPS - Diluted

FY2025Q2

YoY :

+44.00%

-41.02M

Free Cash Flow

FY2025Q2

YoY :

-159.60%

-4.13

Gross Profit Margin - %

FY2025Q2

YoY :

+261.35%

-7.48

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 672.59% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

220.0K

USD

Months

0-12

95.7K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

1.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 672.59% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

220.0K

USD

Months

0-12

95.7K

USD

Months

AGL News & Events

Events Timeline

2025-08-04 (ET)

2025-08-04

16:14:20

Agilon Health suspends FY25 guidance

2025-08-04

16:14:01

Agilon Health reports Q2 EPS (25c), consensus (11c)

2025-08-04

16:12:51

Agilon Health CEO Sell steps down

News

7.0

08-11Globenewswire

AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Agilon Stockholders and Encourages Investors to Contact the Firm

7.0

08-09Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL

7.0

08-06PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL